Ribodoxo® 2 mg/ml Injektionslösung
Sponsors
BioNTech SE, AstraZeneca AB
Conditions
Endometrial cancerLarge B-cell Lymphoma
Phase 3
A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer
RecruitingCTIS2023-507525-42-00
Start: 2025-12-23Target: 222Updated: 2025-11-17
A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 followed by AZD0486 versus R-mini-CHOP x6 in Elderly or Unfit Participants with Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)
Not yet recruitingCTIS2025-522029-37-00
Target: 14Updated: 2026-01-30